Volumetric Visual Fields at Intermediate and Near Distances in Presbyopic Patients Using Occupational and General-Purpose Progressive Addition Lenses
CIVIUS2025PAL
Ensayo clínico, unicéntrico, Transversal, Randomizado, Cruzado, Doble Ciego Para Evaluar Las Diferencias de Los Campos volumétricos de visión en Distancia Intermedia (4m) y Cerca (25cm) de Tres Tipos de Lentes oftálmicas de adición Progresiva (PAL), Dos de visión Intermedia y Cerca (PC-PAL) y Otra Generalista de Vision Lejos, Intermedia y Cerca (GPPAL), Neutros en Vision de Lejos y de 2.00 D en Vision de Cerca en Pacientes présbitas.
2 other identifiers
interventional
26
1 country
1
Brief Summary
This single-center, randomized, double-blind, crossover clinical trial aims to compare the volumetric visual fields provided by two occupational progressive addition lenses (OPLs) optimized for intermediate and near vision in presbyopic patients. The study evaluates Vimax Zoom 1.5 FWD 4 m and Vimax PC 1.5 FWD 4 m lenses and Vimax Fit FRM, all of them with plano distance power and a +2.00 D near addition, in order to determine differences in the extent of clear vision at multiple working distances. Participants will undergo a comprehensive optometric examination including medical and ocular history, visual acuity assessment, accommodative amplitude measurement, autorefraction, interpupillary distance measurement, ocular motility evaluation, confrontation visual fields, Amsler grid testing, and binocular vision assessment. Visual field measurements will then be performed using both study lenses under standardized conditions. Subjects will be instructed to maintain a fixed head position while identifying optotypes located at distances of 4 m, 2 m, 1.33 m, 80 cm, 40 cm, and 25 cm. Both lenses will be tested in random order under masked conditions so that neither participants nor investigators know which lens design is being evaluated during each phase. At least 23 presbyopic participants are expected to be enrolled. The study procedures are non-invasive and are anticipated to be completed in a single one-hour visit, although additional sessions may be scheduled if necessary. No significant risks are expected beyond possible transient visual fatigue associated with the duration of testing. The primary objective is to determine which occupational progressive lens design provides a greater spatial volume of clear vision and wider horizontal and vertical visual fields at different intermediate and near distances. The findings may contribute to improving personalized recommendations of occupational lenses according to patients' visual demands and working distances.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 29, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 28, 2025
CompletedFirst Submitted
Initial submission to the registry
May 14, 2026
CompletedFirst Posted
Study publicly available on registry
June 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2026
ExpectedJune 1, 2026
May 1, 2026
2 months
May 14, 2026
May 23, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Visual field volume
It will consist of the volume defined by two parallel surfaces bounded by the visual fields perceived with clear horizontal and vertical vision by the patient between the distances of 4 m and 25 cm while wearing each pair of spectacles. The volume will be calculated using the Heronian formula for the volume of a quadrangular pyramidal frustum.
Immediately after the adjustment of the frame where the lenses were placed, an average of 30 minutes per patient.
Secondary Outcomes (1)
Visual fields surface
Immediately after the adjustment of the frame where the lenses were placed, an average of 30 minutes per patient.
Study Arms (3)
OPL designed for PC use
EXPERIMENTALVIMAX PC: Occupational progressive lenses designed to provide clear vision from 400 cm to 40 cm, with a wider visual field optimized for monitor-based environments with a depth of field between 60 and 80 cm. These lenses, designated L1, were custom ordered with neutral distance power and a near addition of +2.00 D, a vertex distance of 13 mm, pantoscopic tilt of 8°, wrap angle of 6°, working distance of 40 cm, inset of 2.5 mm in both eyes, and NPD of 31 mm in each eye.
OPL designed for office use
EXPERIMENTALVIMAX ZOOM: Occupational progressive lenses also designed to provide clear vision from 400 cm to 40 cm, but with a more homogeneous distribution of the visual field across office and home environments, with a depth of field between 40 and 400 cm. These lenses, designated L2, were also custom ordered with neutral distance power and a near addition of +2.00 D, vertex distance of 13 mm, pantoscopic tilt of 8°, wrap angle of 6°, working distance of 40 cm, inset of 2.5 mm in both eyes, and NPD of 31 mm in both eyes.
PAL
ACTIVE COMPARATORVIMAX FIT: Progressive additional lenses custom ordered with neutral distance power and a near addition of +2.00 D, vertex dis-tance of 13 mm, pantoscopic tilt of 8°, wrap angle of 6°, working distance of 40 cm, inset of 2.5 mm in both eyes, and NPD of 31 mm in both eyes.
Interventions
Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist. Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order
Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist. Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order
Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist. Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order
Eligibility Criteria
You may qualify if:
- Spherical ametropia for distance vision ≤ ±4.00 D and astigmatic ametropia ≤ 1.00 D.
- Decimal VA ≥ 0.8, either uncorrected (UCVA) or corrected (BCVA) with monofocal contact lenses.
- Patients with a nasopupillary distance (NPD) of 31 mm, with a tolerance of ±2 mm in each eye
You may not qualify if:
- Astigmatism greater than ±1.00 D.
- Patients wearing progressive contact lenses.
- Patients who have undergone cataract surgery or have monofocal or multifocal intraocular lenses.
- Anisometropia greater than 2.50 D.
- Decimal distance visual acuity \< 0.8 (UCVA or BCVA) with monofocal contact lenses.
- Patients without normal ocular motility or with partial dysfunction of one or more ex-traocular muscles, or with restricted visual fields or scotomas.
- Visual suppression in one eye between 4 m and 25 cm.
- Strabismus or nystagmus.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Pharmacy school, University of Seville
Seville, Sevilla, 41012, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Masking Details
- A code was assigned to each participant and echa type of lenses. Investigators don't know which lens are being assessed during the trial.
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Optometry degree, Pharmacy degree and PhD in Molecular Biology, Biomedicine and Clinical Research
Study Record Dates
First Submitted
May 14, 2026
First Posted
June 1, 2026
Study Start
September 29, 2025
Primary Completion
November 28, 2025
Study Completion (Estimated)
September 1, 2026
Last Updated
June 1, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share